Cambrex opens large-scale capacity expansion at its Karlskoga facility

Cambrex and AstraZeneca open capacity expansion at the Karlskoga, Sweden facility.

Opening ceremony marks long-term supply agreement between Cambrex and AstraZeneca for a key intermediate.

The announcement follows the completion, in 2017, of both a large-scale, multi-purpose capacity expansion which also includes hydrogenation capabilities and a dedicated continuous flow production unit capable of producing multiple metric tons of high purity advanced intermediates per annum at the Karlskoga facility.

Speaking at the ceremony, Juliette White, VP Global External Sourcing, AstraZeneca, commented: “Cambrex was selected as our manufacturing partner on this long-term intermediate supply agreement as they clearly demonstrated a robust technically and commercially attractive solution, as well as having a good track record in terms of performance and delivery.” She added, “We look forward to a successful collaboration with Cambrex.”

Shawn Cavanagh, COO of Cambrex, stated: “We have an excellent relationship with AstraZeneca dating back to the 1950s and are excited to partner with them on the long-term production of several important products.” He added, “We will continue to invest in capabilities, technology and appropriate capacity at the Karlskoga site in line with AstraZeneca’s ambitious targets and on-going customer demand.”